

Response dated September 30, 2004

Reply to Office action mailed April 1, 2004

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:


Claims 1-10 (cancelled)

Claim 11 (new):

A method of preventing platelet aggregation in a patient comprising administering to a patient in need thereof an effective amount of a ketolide or its non-toxic, pharmaceutically acceptable acid addition salts sufficient to inhibit platelet aggregation in said patient.

Claim 12 (new):

The method of claim 11 wherein the ketolide has the formula



I

wherein R is $-(CH_2)_mO_n(X)YAr$, m and n are individually 0 or 1, X is selected from the group consisting of $-(NH)_a-$, $-CH_2-$ and $-SO_2-$, a is 0 or 1, Y is $-(CH_2)_b-(CH=CH)_c-(CH_2)_d$, c

Response dated September 30, 2004

Reply to Office action mailed April 1, 2004

is 0 or 1, $b + c + d \leq 8$, Z is hydrogen or halogen and Ar is unsubstituted or substituted aryl or heteroaryl.

Claim 13 (new):

The method of claim 11 wherein the ketolide is orally administered at 50 to 500 mg per day.

Claim 14 (new):

The method of claim 11, wherein the ketolide is 11,12-dideoxy-3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribohexopyranosyl)oxy]-6-O-methyl-3-oxo-12,11-([oxycarbonyl]([2-[4-(3-pyridinyl)-1H-imidazol-1-yl]ethoxy]-methyl]imino))erythromycin.

Claim 15 (new):

The method of claim 11, wherein the ketolide is 11,12-dideoxy-3-de((2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribohexopyranosyl)oxy)-6-O-methyl-3-oxo-12,11-(oxycarbonyl((4-(3-(3-pyridinyl)-1H-1,2,4-triazol-1-yl)butyl)imino))erythromycin.

Claim 16 (new):

The method of claim 11, wherein the ketolide is 11,12-dideoxy-3-de((2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribohexopyranosyl)oxy)-2-fluoro-6-O-methyl-3-oxo-12,11-(oxycarbonyl((4-(4-(3-pyridinyl)-1H-imidazol-1-yl)butyl)imino))erythromycin (A isomer).

Claim 17 (new):

The method of claim 11, wherein the ketolide is 11,12-dideoxy-3-de((2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribohexopyranosyl)oxy)-6-O-methyl-3-oxo-12,11-(oxycarbonyl((4-(4-(3-pyridinyl)-1H-imidazol-1-yl)butyl)imino))erythromycin.